Table 3:

Ongoing trials for potential therapies for heart failure with preserved ejection fraction (HFpEF)

Intervention	Trial name	Clinical trial registration number	Primary outcome
Management of comorbidities	OPTIMIZE-HFPEF	NCT02425371	Clinical score status
Empagliflozin (SLGT-2 inhibitor)	EMPEROR-Preserved	NCT03057951	Composite of cardiac mortality or HF hospitalizations
Dapagliflozin (SLGT-2 inhibitor)	PRESERVED-HF	NCT03030235	Natriuretic peptide levels
Spironolactone	SPIRRIT	NCT02901184	All-cause mortality
Neprilysin inhibitors	PARAGON-HF	NCT01920711	Composite of cardiac mortality or HF hospitalizations
Neprilysin inhibitors	PARALLAX	NCT03066804	Quality of life
Sildenafil	PASSION	DRKS00014595	Composite of all-cause mortality or HF hospitalizations

HF=heart failure; SLGT-2 inhibitor= sodium-glucose cotransporter-2 inhibitors